The

nuvision-logo-whiteTeam

NuVision is managed by an expert team of directors encompassing essential skills of business development, clinical ophthalmic surgery, medical affairs, GMP manufacturing and research and development. Together we create a unique dynamic that will enable the company to grow and evolve to redefine sight saving biotherapies.
Dr Mark Treherne

Dr Mark Treherne

Chairman

treherne@nu-vision.co.uk
Mark Treherne joined the NuVision team in 2018 as Chairman of the company. Mark has a PhD in Pharmacology from Cambridge University along with over 25 years of industrial R&D experience in the discovery and development of novel treatments for diseases with unmet medical need. Mark is also currently Chairman of Talisman Therapeutics and Chief Executive of Avilex Pharma.

Prior to this, Mark has carried out research work with Pfizer and in 1997 set up Cambridge Drug Discovery (CDD) as Chief Executive which was sold to BioFocus in 2001.

Mark was formerly Chairman of ERBI for 3 years, which represents the biotechnology companies in the East of England (now One Nucleus). He was also Chief Executive of the Life Sciences Organisation of UK Trade & Investment until 2016. Mark is an author of over 70 articles published in the scientific and trade press.

Andrew Hopkinson, PhD, is the Chief Executive Officer, founder and visionary of NuVision. Andrew has 15 years’ translational research expertise in ophthalmic regenerative medicine as the Principal Research Fellow at Nottingham Centre For Eye research, which is part of Academic Ophthalmology, Division of Clinical Neurosciences, University of Nottingham.

During his time at the University he and his multidisciplinary research team have been engaged in developing innovative technologies to repair and regenerate the injured ocular surface for visual rehabilitation. His research pioneered the development of Tereo processing and Omnigen. He continues to drive ground breaking research discoveries from the bench to pre-clinical and clinical realisation, to create an exciting future portfolio of innovative Biotherapies for NuVision.

During his academic career, Dr Hopkinson has published over 50 scientific papers in leading journals in the fields of ophthalmology and tissue engineering, and has filed 4 patents.

Dr Andrew Hopkinson

Dr Andrew Hopkinson

Chief Scientific Officer

hopkinson@nu-vision.co.uk
Roger Teasdale

Roger Teasdale

Independent Non-Executive Director

Roger Teasdale joined the Board as an Independent Non-Executive Director in 2018. Roger enjoyed a successful 25 year career at Smith & Nephew, the FTSE 100 Medical device business focused on the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of $4.8bn and operations in 120 countries. For his last 5 years at Smith & Nephew, Roger was President of the Global Advanced Wound Management business with sales of $1.4bn and 4000 people in 80 countries. Roger gained a proven international track record in driving revenue and profit growth in the medical device industry. His most recent role is Group Managing Director at Premier Technical Services Group, a listed niche specialist service provider. Roger is a qualified Chartered Accountant and holds a BA in Accounting and Management Control.

Adrian Del Arenal Martin is a Biotechnology Engineer from the Monterrey Institute of Technology in Mexico. He has pilot plant lab experience with recombinant protein bioprocessing. He also graduated from the University of Nottingham with a MSc. in Biopharmaceutics and Business and has gained start-up business knowledge as a intern SME consultant at BioCity.

Adrian joined the team in 2017 as a Intern Manufacturing Technician, and since summer 2018, he has been appointed as the Operations Manager for the company. He is now the responsible for overseeing procurement, human resources, sales order processing and other general operations areas

Adrian Del Arenal

Adrian Del Arenal

Operations Manager

Maria Mendoza

Maria Mendoza

Quality Manager

María J. Mendoza is the Quality Manager at NuVision. Her experience includes molecular, cell biology and immunology research. Graduated from the University of Nottingham with a MSc. in Stem Cell Technology, she has knowledge of regenerative therapies and translational technologies. As an intern in NuVision, Maria has been involved in the translation and implementation of Omnigen manufacture into clinical standards. Then she became production manager overseeing Omnigen manufacture, process development and translation of new research technologies into clinical standards following the HTA requirements.

Geert joined NuVision as our HTA Designated Individual & Regulatory Manager in 2019. He was introduced to tissue banking in 2002 while managing one of only two heart valve banks in South-Africa during which he was responsible for ensuring a national supply of quality-controlled cryopreserved human cardiac valves for transplant in South Africa as well as export to Germany. In 2004 he expanded his focus to include a program for the processing of frozen and dehydrated human amniotic membrane-based therapies for ophthalmic use in South Africa, later extending the programme to include the production of umbilical cord blood serum eye drops. Since moving to the UK Geert has continued his focus in tissue banking. In 2017 he joined Moorfield Eye Hospital as the Manager and Designated Individual for the Moorfields Lions Eye Bank.

Geert holds a Master’s Degree in Biological Science from the University of South Africa, a Bachelor’s degree in Veterinary Reproductive Sciences and Molecular Biology from the Tshwane University of Technology and a Diploma in Tissue Banking from the Universitat De Barcelona. He is experienced in ISO 9001 and ISO 13485 Quality Management Systems.

Geert Kuit

Geert Kuit

Designated Individual and Regulatory Manager

Adrian Hamblin

Adrian Hamblin

International Distributor Executive

Adrian joined NuVision in 2019 having recently returned to the UK. A senior manager with over 20 years of success working in the pharmaceutical and medical device industries.

Adrian has gained a diverse cross cultural experience from working across the MENA and ASEAN regions and has undertaken a variety of senior management roles. His latest position overseeing all aspects of the equipment sales for IDS Medical Systems (Vietnam),  part of the Li and Fung corporation. Adrian has previously been involved in the growth and sale of SME. He has a keen interest in wildlife and conservation; his last year in Southeast Asia volunteering in a gibbon sanctuary in Thailand.

Dr Emily Britchford is the Research and Development Officer at NuVision. She has several years’ experience in both academic and applied scientific research. Emily has recently graduated with a PhD in Tissue Engineering at the University of Nottingham as part of the EPSRC doctoral training program in regenerative medicine.

Emily has a dual role also working as a post-doctoral research associate in Academic Ophthalmology at the University of Nottingham. Her research interests focus on the development of Omnigen application for acute ocular surface trauma.

Dr Emily Britchford

Dr Emily Britchford

Research and Development Officer

Tonicha Spencer

Tonicha Spencer

Medical Science Liaison

Tonicha Spencer is the Medical Science Liaison at NuVision. Following an internship, Tonicha joined NuVision in 2018 after completing a Master’s  degree in Medicinal Chemistry from the University of Leeds. Tonicha is involved in aiding clinical research regarding Omnigen for application in ophthalmology.

 

Our highly skilled dedicated manufacturing team responsible for creating our flagship product Omnigen.

Duncan Rawlins and Joseph Brown

Duncan Rawlins and Joseph Brown

Manufacturing Technicians

Interested in purchasing Omnigen?

Register your interest

Have a question about our products or pipelines?

Speak to our team of experts